IP : DeepMatter Group plc - Appointment of new Scientific Advisory Board

Professor Richard Bourne to head up DeepMatter's new Scientific Advisory Board

DeepMatter Group Plc (AIM: DMTR, "DeepMatter", the "Group"), the international digital chemistry data company, has created a new Scientific Advisory Board ("SAB") to be led by Professor Richard Bourne, who was recently promoted to Professor at the University of Leeds and appointed Research Chair of Royal Academy of Engineering.

The SAB, which is made up of sector Key Opinion Leaders, will work closely with the whole team at DeepMatter as it builds its unique, fully integrated digital chemistry platform, which ultimately will enable AI-driven chemical automation.

The SAB is made up of:

· Dr Richard Bourne, Professor of Digital Chemical Manufacturing at the University of Leeds. He is a leading academic in Process Chemistry and brings considerable expertise in automated flow systems combining online analysis, feedback control and evolutionary algorithms to provide process understanding and optimisation. Richard is also Royal Academy of Engineering Research Chair working on Digital Discovery and Manufacturing of Pharmaceuticals.

· Dr Nessa Carson, Principal Automation Scientist at Syngenta. She brings a wealth of practical experience in a range of automated synthesis and optimisation capabilities and their application in both discovery and process research.

· Dr Natalie Fey, an expert in computational approaches as Associate Professor at the Centre for Computational Chemistry, University of Bristol. Natalie strengthens its commitment to utilising state of the art computational tools to enhance the efficiency of chemistry through effective use of data.

· Dr David Parry, Head of Research at DeepMatter. David is an experienced synthetic chemist and technologist, with a track record of delivering complex projects within the pharma and biotech sector.

· Dr Bryn Roberts, SVP and Head of Data Services at Roche Information Solutions and non-executive director at DeepMatter. Bryn brings a wealth of experience in the pharmaceutical sector having spent 15 years at Roche, the Swiss multinational healthcare company. Prior to his current role he was Global Head of Operations, Pharmaceutical Research & Early Development.

Mark Warne, CEO of DeepMatter, commented:

"I am delighted that these key opinion leaders have joined us. They are all recognised across the industry as being at the forefront of research and development in the digitalisation of chemistry.

"Their combined and considerable expertise will be invaluable as we continue building a unique, fully integrated digital chemistry cloud platform of chemical reaction data for scientists."

For more information, contact:

DeepMatter Group Plc

Mark Warne, Chief Executive Officer 0141 548 8156

Canaccord Genuity Limited (Nominated Advisor and Broker) 020 7523 8000

Bobbie Hilliam

Meare Consulting 07990 858548

Adrian Duffield

About DeepMatter Group plc

DeepMatter is building a unique, fully integrated digital chemistry cloud platform of chemical reaction data for scientists, who are working on early-stage chemical discovery & development.

DeepMatter is integrating technology with chemistry to enable scientists, principally in the commercial sector, to easily perform and optimise chemistry. It is building, structuring and analysing chemical reaction databases and using this substantial data for real-time innovation and productivity gains in the chemical industry - particularly pharmaceutical companies engaged in pre-clinical drug discovery & development. This data is also now enabling Artificial Intelligence (AI) driven chemical automation.

Visit: www.deepmatter.io and follow @deepmattergroup